Книга: С ума сойти! Путеводитель по психическим расстройствам для жителя большого города
Назад: Благодарности
Дальше: Список фильмов и книг для тех, кому интересна психиатрия

Примечания

  1. Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15–4927, NSDUH Series H-50). Retrieved from http://www.samhsa.gov/data/
  2. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM–IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005 Jun; 62(6): 617–27.
  3. Lenzenweger MF, Lane MC, Loranger AW, Kessler RC (2007). DSM–IV personality disorders in the National Comorbidity Survey Replication. Biological Psychiatry, 62(6), 553–564.
  4. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto mental and addictive disorders service system. Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry. 1993 Feb; 50(2): 85–94.
  5. Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15–4927, NSDUH Series H-50). Retrieved from http://www.samhsa.gov/data/
  6. http://ria.ru/society/20141010/1027775155.html
  7. Kessler RC, Angermeyer M, Anthony Jc, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry. 2007; 6(3): 168–176.
  8. http://gutta-honey.livejournal.com/113296.html
  9. Marazziti D, Akiskal HS, Rossi A, Cassano GB. Alteration of the platelet serotonin transporter in romantic love. Psychol Med. 1999 May; 29(3): 741–5.
  10. Bentall RP. A proposal to classify happiness as a psychiatric disorder. Journal of Medical Ethics. 1992; 18(2): 94–98.
  11. https://www.youtube.com/watch?v=G_Qwp2GdB1M
  12. Dima D, Roiser JP, Dietrich DE, Bonnemann C, Lanfermann H, Emrich HM, Dillo W. Understanding why patients with schizophrenia do not perceive the hollow-mask illusion using dynamic causal modelling. Neuroimage. 2009 Jul 15; 46(4): 1180–6. doi: 10.1016/j.neuroimage.2009.03.033. Epub 2009 Mar 24.
  13. Rosenhan DL. On being sane in insane places. Science. 1973 Jan 19; 179(4070): 250–8.
  14. Progler Y. Mental illness and social stigma: notes on "How Mad Are You?" Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2009; 14(5): 331–334.
  15. Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord. 2009. Se; 117(1–2): 1–17.
  16. Contribution of depression to cognitive impairment and dementia in older adults. Neurologist. 2007 May; 13(3): 105–17.
  17. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.). Arlington, VA: American Psychiatric Publishing, p. 20. ISBN978–0–89042–555–8.
  18. Dalgleish T. The emotional brain. Nat Rev Neurosci. 2004 Jul; 5(7): 583–9. Review.
  19. Mega MS, Cummings JL, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci. 1997 Summer; 9(3): 315–30. Review.
  20. Robert Sapolsky (2005). "Biology and Human Behavior: The Neurological Origins of Individuality, 2nd edition". The Teaching Company, p. 13 & 14 of Guide Book.
  21. Nichols DE. Hallucinogens. Pharmacol Ther. 2004 Feb; 101(2): 131–81. Review.
  22. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003 Jun; 63(6): 1223–9.
  23. Kennett GA, Ainsworth K, Trail B, Blackburn TP. BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology. 1997 Feb; 36(2): 233–9.
  24. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5; 102(23): 2836–41.
  25. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr; 26(2): 137–44. Review.
  26. Hofmann A. (1983). LSD, my problem child: Reflections on sacred drugs, mysticism, and science. Los Angeles: J. P. Tarcher. P. 21.
  27. Andersson A, Wiréhn A-B, Ölvander C, Ekman DS, Bendtsen P. Alcohol use among university students in Sweden measured by an electronic screening instrument. BMC Public Health. 2009;9:229. doi: 10.1186/1471–2458–9–229.
  28. Kellett J, Kokkinidis L. Extinction deficit and fear reinstatement after electrical stimulation of the amygdala: implications for kindling-associated fear and anxiety. Neuroscience. 2004; 127(2): 277–87.
  29. Ghaemi SN. The rise and fall of the biopsychosocial model. Br J Psychiatry. 2009 Jul; 195(1): 3–4. doi: 10.1192/bjp.bp.109.063859.
  30. Haygarth, John. (1800). Of the imagination, as a cause and as a cure of disorders of the body; exemplified by fictitious tractors, and epidemical convulsions. Read to the Literary and Philosophical Society of Bath. By John Haygarth, M.D. … Bath: printed by R. Cruttwell; and sold by Cadell and Davies, London.
  31. Beecher HK. The powerful placebo. J Am Med Assoc. 1955; 159(17): 1602–6.
  32. Howick J, Friedemann C, Tsakok M, et al. Are treatments more effective than placebos? A systematic review and meta-analysis. PLoS ONE. 2013; 8(5): e62599.
  33. Linde K, Fässler M, Meissner K. Placebo interventions, placebo effects and clinical practice. Philos Trans R Soc Lond, B, Biol Sci. 2011; 366(1572): 1905–12.
  34. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008; 65(2): 220–31.
  35. Oken BS. Placebo effects: clinical aspects and neurobiology. Brain. 2008; 131(Pt 11): 2812–23.
  36. Matre D, Casey KL, Knardahl S. Placebo-induced changes in spinal cord pain processing. J Neurosci. 2006; 26(2): 559–63.
  37. Qiu YH, Wu XY, Xu H, Sackett D. Neuroimaging study of placebo analgesia in humans. Neurosci Bull. 2009; 25(5): 277–82.
  38. Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci. 2009; 1156: 198–210.
  39. Lidstone SC, Stoessl AJ. Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol. 2007; 9(4): 176–85.
  40. Misra S. Randomized double blind placebo control studies, the "Gold Standard" in intervention based studies. Indian Journal of Sexually Transmitted Diseases. 2012; 33(2): 131–134.
  41. Levine R. A Real Mental Ward Becomes A Movie 'Cuckoo's Nest'. The New York Times. April 13, 1975. http://www.nytimes.com/packages/html/movies/bestpictures/cuckoo-ar1.html. Accessed Feb 25, 2016.
  42. Tooth GC, and Newton, MP: Leukotomy in England and Wales 1942–1954. London, Her Majesty's Stationary Office, 1961.
  43. Jansson B. Controversial Psychosurgery Resulted in a Nobel Prize. Nobel Media AB2014. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1949/moniz-article.html. Accessed Feb 25, 2016.
  44. Soares MS, Paiva WS, Guertzenstein EZ, et al. Psychosurgery for schizophrenia: history and perspectives. Neuropsychiatric Disease and Treatment. 2013; 9: 509–515.
  45. http://www.youtube.com/watch?v=yQa_sg4zN88
  46. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003; 361(9360): 799–808.
  47. Fitzgerald PB. Non-pharmacological biological treatment approaches to difficult-to-treat depression. Med J Aust. 2013; 199(6 Suppl): 48–51.
  48. Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. 2nd ed. Washington, DC: American Psychiatric Publishing, 2001.
  49. MacQueen G, Parkin C, Marriott M, Bégin H, Hasey G. The long-term impact of treatment with electroconvulsive therapy on discrete memory systems in patients with bipolar disorder. Journal of Psychiatry & Neuroscience. 2007; 32(4): 241–249.
  50. Coentre R, Barrocas D, Chendo I, et al. [Electroconvulsive therapy: myths and evidences]. Acta Med Port. 2009; 22(3): 275–80.
  51. Cristancho MA, Alici Y, Augoustides JG, O'reardon JP. Uncommon but serious complications associated with electroconvulsive therapy: recognition and management for the clinician. Curr Psychiatry Rep. 2008; 10(6): 474–80.
  52. Wilkins KM, Ostroff R, Tampi RR. Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature. J Geriatr Psychiatry Neurol. 2008; 21(1): 3–11.
  53. Golenkov A, Ungvari GS, Gazdag G. Public attitudes towards electroconvulsive therapy in the Chuvash Republic. Int J Soc Psychiatry. 2012; 58(3): 289–94.
  54. Martin CD. Ernest Hemingway: a psychological autopsy of a suicide. Psychiatry. 2006; 69(4): 351–61.
  55. Swartz C. Electroconvulsive and Neuromodulation Therapies. Cambridge University Press; 2009. P. 185–187.
  56. Leopold T. (2016, November 18), Sam Phillips, Elvis and the invention of rock 'n' roll, CNN, Available at: http://edition.cnn.com/2015/11/18/entertainment/sam-phillips-sun-records-guralnick-feat/. Accessed February 24, 2016.
  57. Rawsthorn A. Yves Saint Laurent, a biography. Nan A. Talese; 1996.
  58. The Atlantic Monthly; January 1996; Bud's Bubble; Volume 277, No. 1; pages 99–102.
  59. Gardiner H. & Carey B., Researchers Fail to Reveal Full Drug Pay, The New York Times, Jun 8, 2008.
  60. Мартынихин И. О состоянии стационарных психиатрических учреждений РФ, Российское общество психиатров (6 декабря 2013 год, 09:35). http://psychiatr.ru/news/192
  61. Reininghaus U, Priebe S, Bentall RP. Testing the Psychopathology of Psychosis: Evidence for a General Psychosis Dimension. Schizophrenia Bulletin. 2013; 39(4): 884–895.
  62. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381(9875): 1371–9.
  63. Maj M. «Psychiatric comorbidity»: an artefact of current diagnostic systems?. Br J Psychiatry. 2005;186: 182–4.
  64. Reininghaus U, Priebe S, Bentall RP. Testing the Psychopathology of Psychosis: Evidence for a General Psychosis Dimension. Schizophrenia Bulletin. 2013; 39(4): 884–895.
  65. Wampold BE, Minami T, Tierney SC, Baskin TW, Bhati KS. The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol. 2005; 61(7): 835–54.
  66. World Health Organization. (1992). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.
  67. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys. Epidemiologia e psichiatria sociale. 2009; 18(1): 23–33.
  68. Ciftci, Ayse, Nev Jones, and Patrick W. Corrigan. "Mental Health Stigma In The Muslim Community". Journal of Muslim Mental Health 7.1 (2013): n. pag. Web.
  69. Xu JM. Some issues in the diagnosis of depression in China. Can J Psychiatry. 1987; 32(5): 368–70.
  70. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013; 10(11).
  71. Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013; 43(5): 897–910.
  72. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys. Epidemiologia e psichiatria sociale. 2009; 18(1): 23–33.
  73. www.youtube.com/watch?v=NXB6slJSbL4
  74. Saint Martin ML. Running Amok: A Modern Perspective on a Culture-Bound Syndrome. Primary Care Companion to The Journal of Clinical Psychiatry. 1999; 1(3): 66–70.
  75. http://theoryandpractice.ru/posts/11759-sosland
  76. Ablow K., We are raising a generation of deluded narcissists, Fox News, January 08, 2013.
  77. Compton WM, Conway KP, Stinson FS, Grant BF. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991–1992 and 2001–2002. Am J Psychiatry. 2006; 163(12): 2141–7.
  78. Andrade L, Caraveo-anduaga JJ, Berglund P, et al. The epidemiology of m. Int J Methods Psychiatr Rajor depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. 2003; 12(1): 3–21.
  79. Twenge JM, Gentile B, Dewall CN, Ma D, Lacefield K, Schurtz DR. Birth cohort increases in psychopathology among young Americans, 1938–2007: A cross-temporal meta-analysis of the MMPI. Clin Psychol Rev. 2010; 30(2): 145–54.
  80. Hollan DW, Wellenkamp JC. Contentment and suffering: Culture and experience in Toraja. Columbia Univ Pr; 1994.
  81. Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. Journal of Affective Disorders. 2012; 140(3): 205–214. doi: 10.1016/j.jad.2011.12.036.
  82. Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. Journal of Affective Disorders. 2012; 140(3): 205–214. doi: 10.1016/j.jad.2011.12.036.
  83. Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. Journal of Affective Disorders. 2012; 140(3): 205–214. doi: 10.1016/j.jad.2011.12.036.
  84. Hibbeln JR. Fish consumption and major depression. Lancet. 1998; 351(9110): 1213.
  85. Kitayama S, Markus HR, Matsumoto H, Norasakkunkit V. Individual and collective processes in the construction of the self: self-enhancement in the United States and self-criticism in Japan. J Pers Soc Psychol. 1997; 72(6): 1245–67.
  86. World Health Organization. Global health estimates 2014 summary tables: YLD estimates, 2000–2012, Available: http://www.who.int/entity/healthinfo/global_
    burden_disease/GHE_YLD_Global_2000_2012.xls. Accessed 20 September 2010.
  87. Merikangas KR, He J, Burstein M, et al. Lifetime Prevalence of Mental Disorders in US Adolescents: Results from the National Comorbidity Study-Adolescent Supplement (NCS-A). Journal of the American Academy of Child and Adolescent Psychiatry. 2010; 49(10): 980–989. doi:10.1016/j.jaac.2010.05.017.
  88. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U. S. Department of Health and Human Services; 2014.
  89. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS data brief, no 94. Hyattsville, MD: National Center for Health Statistics. 2012.
  90. Prevalence of mood disorders in the rural population of Udmurtia. Pakriev, Acta Psychiatr Scand. 1998 Mar; 97(3): 169–74.
  91. Simon GE, VonKorff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med 1995; 4: 99–105.
  92. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1994.
  93. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.
  94. Tsuang MT, Taylor L, Faraone SV. An overview of the genetics of psychotic mood disorders. J Psychiatr Res. 2004; 38: 3–15.
  95. Nutt DJ (2008). "Relationship of neurotransmitters to the symptoms of major depressive disorder". Journal of Clinical Psychiatry. 69 Suppl E1: 4–7.
  96. Merzenich MM, Nelson RJ, Stryker MP, Cynader MS, Schoppmann A, Zook JM. Somatosensory cortical map changes following digit amputation in adult monkeys. J Comp Neurol. 1984; 224(4): 591–605.
  97. Davidson RJ, McEwen BS. Social influences on neuroplasticity: Stress and interventions to promote well-being. Nature neuroscience. 2012; 15(5): 689–695. doi: 10.1038/nn. 3093.
  98. Castrén E, Rantamäki T. Neurotrophins in depression and antidepressant effects. Novartis Found Symp. 2008; 289: 43–52.
  99. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010; 70(5): 289–97.
  100. Goldman-Rakic PS (October 1996). The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 351(1346): 1445–53.
  101. X.T. Wang and Robert D. Dvorak. Sweet Future: Fluctuating Blood Glucose Levels Affect Future Discounting. Psychological Science, 21, 183–188.
  102. Maes M. "Functional" or "psychosomatic" symptoms, e. g. a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinol Lett. 2009; 30(5): 564–73.
  103. Ryan KA, Dawson EL, Kassel MT, et al. Shared dimensions of performance and activation dysfunction in cognitive control in females with mood disorders. Brain. 2015; 138(Pt 5): 1424–34.
  104. Mackin P, Young AH, The Role of Cortisol and Depression: Exploring New Opportunities for Treatments, Psychiatric Times, 2004; 21: 92–5.
  105. Herbert J. Cortisol and depression: three questions for psychiatry. Psychol Med. 2013; 43(3): 449–69.
  106. Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(22): 12320–12322.
  107. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. Hay PJ, ed. PLoS Medicine. 2013; 10(11): e1001547.
  108. Соломон Э. Демон полуденный: Анатомия депрессии. — М.: Доб­рая книга, 2004.
  109. Chronic Health Problems among U. S. Adults, by Poverty Status, 2011, Gallup Healthways Well-Being Index.
  110. Jonassen R, Chelnokova O, Harmer C, Leknes S, Landrø NI. A single dose of antidepressant alters eye-gaze patterns across face stimuli in healthy women. Psychopharmacology (Berl). 2015; 232(5): 953–8.
  111. Selikoff IJ, Robitzek EH. Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid. Dis Chest. 1952; 21(4): 385–438.
  112. Burn JH. The Antihistamine Compounds. British Medical Journal. 1958; 2(5100): 845–846.
  113. Pletscher A. The discovery of antidepressants: a winding path. Experientia. 1991; 47(1): 4–8.
  114. Fagius J, Osterman PO, Sidén A, Wiholm BE. Guillain-Barré syndrome following zimeldine treatment. Journal of Neurology, Neurosurgery, and Psychiatry. 1985; 48(1): 65–69.
  115. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998; 59 Suppl 15: 42–8.
  116. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006; 163(1): 41–7.
  117. Dunlop BW, Davis PG. Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression: A Review. Primary Care Companion to The Journal of Clinical Psychiatry. 2008; 10(3): 222–228.
  118. Постановление Правительства Российской Федерации от 4 февраля 2013 г. № 78 г. Москвы «О внесении изменений в некоторые акты Правительства Российской Федерации».
  119. Boyce P, Judd F. The place for the tricyclic antidepressants in the treatment of depression. Aust N Z J Psychiatry. 1999; 33(3): 323–7.
  120. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, Severity, and Comorbidity of Twelve-month DSM–IV Disorders in the National Comorbidity Survey Replication (NCS-R). Archives of general psychiatry. 2005; 62(6): 617–627. doi: 10.1001/archpsyc.62.6.617.
  121. Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther. 2010; 35(2): 177–88.
  122. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother. 2001; 35(12): 1608–13.
  123. Pagnin D, De queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004; 20(1): 13–20.
  124. Beltman MW, Voshaar RC, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: meta-analysis of randomised controlled trials. Br J Psychiatry. 2010; 197(1): 11–9.
  125. Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008; 69(4): 621–32.
  126. U. S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health. (2015). Mental Health Information: Depression. Retrieved from http://www.nimh.nih.gov/health/topics/depression/index.shtml.
  127. Manber R, Kraemer HC, Arnow BA, et al. Faster Remission of Chronic Depression With Combined Psychotherapy and Medication Than With Each Therapy Alone. Journal of consulting and clinical psychology. 2008; 76(3): 459–467. doi: 10.1037/0022–006X.76.3.459.
  128. Lemmens LH, Arntz A, Peeters F, Hollon SD, Roefs A, Huibers MJ. Clinical effectiveness of cognitive therapy v. interpersonal psychotherapy for depression: results of a randomized controlled trial. Psychol Med. 2015; 45(10): 2095–110.
  129. Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2. New York: Oxford University Press; 2007.
  130. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003; 73(1–2): 123–31.
  131. Roccatagliata G. A History of Ancient Psychiatry. Praeger Pub Text; 1986. (pp. 230–231).
  132. Solomon DA, Leon AC, Coryell WH, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry. 2010; 67(4): 339–47.
  133. Jamison KR. An Unquiet Mind, A Memoir of Moods and Madness. Vintage; 2009, p. 36.
  134. Jamison KR. Suicide and Bipolar Disorder. J Clin Psychiatry 2000; 61 (Suppl 9): 47–51.
  135. Solomon DA, Leon AC, Coryell WH, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry. 2010; 67(4): 339–47.
  136. Kerner B. Genetics of bipolar disorder. The Application of Clinical Genetics. 2014; 7: 33–42. doi: 10.2147/TACG.S39297.
  137. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381(9875): 1371–9.
  138. Stein DJ, Kupfer DJ, Schatzberg AF. The American Psychiatric Publishing Textbook of Mood Disorders. American Psychiatric Pub; 2007: 159–75.
  139. Siegel D. Mindsight, Transform Your Brain with the New Science of Kindness. Oneworld Publications; 2010: 80–101.
  140. J. R. Whitwell, Historical Notes on Psychiatry. London: Lewis, 1936.
  141. Andreasen NC. The relationship between creativity and mood disorders. Dialogues in Clinical Neuroscience. 2008; 10(2): 251–255.
  142. Jamison KR. Mood disorders and patterns of creativity in British writers and artists. Psychiatry. 1989; 52(2): 125–34.
  143. Ludwig AM. Creative achievement and psychopathology: comparison among professions. Am J Psychother. 1992; 46(3): 330–56.
  144. Santosa CM, Strong CM, Nowakowska C, Wang PW, Rennicke CM, Ketter TA. Enhanced creativity in bipolar disorder patients: a controlled study. J Affect Disord. 2007; 100(1–3): 31–9.
  145. Kyaga S, Lichtenstein P, Boman M, Hultman C, Långström N, Landén M. Creativity and mental disorder: family study of 300,000 people with severe mental disorder. Br J Psychiatry. 2011;199(5): 373–9.
  146. Frederick K. Googwin, Kay Redfield Jamison. Manic-depressive ilness. Bipolar disorders and reccurent depression. Oxford University Press 2007.
  147. Figueroa c G. [Virginia Woolf as an example of a mental disorder and artistic creativity]. Rev Med Chil. 2005; 133(11): 1381–8.
  148. Ta-Wei Guu, Kuan-Pin Su. Musical creativity and mood bipolarity in Robert Schumann: A tribute on the 200th anniversary of the composer's birth. Psychiatry and Clinical Neurosciences 2011; 65: 112–114.
  149. Stephen G. Michaud, Hugh Aynesworth. The Only Living Witness: The True Story of Serial Sex Killer Ted Bundy.
  150. M. Fink, Delirious mania. Bipolar Disorders, vol. 1, no. 1, pp. 54–60, 1999.
  151. Fazel S, Lichtenstein P, Grann M, Goodwin GM, Långström N. Bipolar disorder and violent crime: new evidence from population-based longitudinal studies and systematic review. Arch Gen Psychiatry. 2010;67(9): 931–8.
  152. https://www.psychologytoday.com/blog/inside-the-criminal-mind/ 201105/bipolar-illness-or-the-ups-and-downs-the-antisocial-persons
  153. Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?. J Affect Disord. 1999; 52(1–3): 135–44.
  154. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. The American journal of psychiatry. 2013; 170(11): 1249–1262. doi: 10.1176/appi.ajp.2013.13020185.
  155. Tohen M, Zarate CA, Hennen J, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003; 160(12): 2099–107.
  156. Simhandl C, König B, Amann BL. A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry. 2014; 75(3): 254–62.
  157. Baethge C, Baldessarini RJ, Mathiske-schmidt K, et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry. 2005; 66(2): 174–82.
  158. Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. International Journal of Bipolar Disorders. 2014; 2: 15. doi: 10.1186/s40345–014–0015–8.
  159. Van der loos ML, Kölling P, Knoppert-van der klein EA, Nolen WA. [Lamotrigine in the treatment of bipolar disorder, a review]. Tijdschr Psychiatr. 2007; 49(2): 95–103.
  160. Rapoport SI, Basselin M, Kim HW, Rao JS. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev. 2009; 61(2): 185–209.
  161. Macritchie K, Geddes JR, Scott J, Haslam D, De lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev. 2003; (1): CD004052.
  162. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194(1): 4–9.
  163. Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. International Journal of Bipolar Disorders. 2014;2:15. doi: 10.1186/s40345–014–0015–8.
  164. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194 (1): 4–9.
  165. Macritchie K, Geddes JR, Scott J, Haslam D, De lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev. 2003; (1): CD004052.
  166. Ushkalova AV, Kostiukova EG, Mosolov SN. [A comparative study of different types of pharmacotherapy in treatment of depressive phase of bipolar II disorder]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115(1 Vypusk 2 Depressiia): 23–30.
  167. Zaretsky AE, Rizvi S, Parikh SV. How well do psychosocial interventions work in bipolar disorder?. Can J Psychiatry. 2007;5 2(1): 14–21.
  168. Frank E, Swartz HA, Mallinger AG, Thase ME, Weaver EV, Kupfer DJ. Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. J Abnorm Psychol. 1999;108(4): 579–87.
  169. Miklowitz DJ. The Bipolar Disorder Survival Guide, Second Edition, What You and Your Family Need to Know. Guilford Press; 2011.
  170. Braga RJ, Burdick KE, Derosse P, Malhotra AK. Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res. 2012; 200(2–3):242–5.
  171. Steimer T. The biology of fear- and anxiety-related behaviors. Dialogues in Clinical Neuroscience. 2002; 4(3): 231–249.
  172. Ohman A, Lundqvist D, Esteves F. The face in the crowd revisited: a threat advantage with schematic stimuli. J Pers Soc Psychol. 2001; 80 (3): 381–96.
  173. Pittman CM, Karle EM. Rewire Your Anxious Brain, How to Use the Neuroscience of Fear to End Anxiety, Panic, and Worry. New Harbinger Publications Incorporated; 2014:16–24.
  174. Гоулман Д. Эмоциональный интеллект. — М.: ACT, 2009.
  175. Amunts K, Kedo O, Kindler M, et al. Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. Anat Embryol. 2005; 210(5–6): 343–52.
  176. Ledoux J. The emotional brain, fear, and the amygdala. Cell Mol Neurobiol. 2003; 23(4–5): 727–38.
  177. Tillich P, Gomes PJ. The Courage to be. New Haven [Conn.]: Yale University Press, 2000.
  178. World Health Organization. Global health estimates 2014 summary tables: YLD estimates, 2000–2012, Available: http://www.who.int/entity/healthinfo/global_
    burden_disease/GHE_YLD_Global_2000_2012.xls. Accessed 8 March 2010.
  179. Dupont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996; 2(4): 167–72.
  180. Lamers F, Van oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2011; 72(3): 341–8.
  181. Kessler RC, Berglund PA, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM–IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry.2005 Jun; 62(6): 593–602.
  182. King, Helen (1993). "Once upon a text: Hysteria from Hippocrates". In Gilman, Sander; King; Porter, Helen; Rousseau, G.S.; Showalter, Elaine. Hysteria beyond Freud. University of California Press.
  183. May R. The Meaning of Anxiety. W. W. Norton; 2015: 40–67.
  184. Ibid.
  185. Kyaga S, Landén M, Boman M, Hultman CM, Långström N, Lichtenstein P. Mental illness, suicide and creativity: 40-year prospective total population study. J Psychiatr Res. 2013 47(1): 83–90.
  186. Silvia, P. J., & Kimbrel, N. A. (in press). A dimensional analysis of creativity and mental illness: Do anxiety and depression symptoms predict creative cognition, creative accomplishments, and creative self-concepts? Psychology of Aesthetics, Creativity, and the Arts.
  187. Dommermuth-Costa C. Nikola Tesla, A Spark of Genius. Twenty-First Century Books; 1994: 19–21.
  188. Jerry Bergman, Ph.D. 2004. Was Charles Darwin Psychotic? A Study of His Mental Health. Acts & Facts. 33 (1).
  189. Panter B, Virshup B. Psychological Studies of Art and Artists. 1996.
  190. Фрейд З. Введение в психоанализ. Лекции. — СПб.: Азбука, 2014..
  191. Izard CE. The Psychology of Emotions. Springer; 2004. 308–12.
  192. Klein DF. Historical aspects of anxiety. Dialogues in Clinical Neuroscience. 2002; 4(3): 295–304.
  193. Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005; 81(2): 341–54.
  194. Grinde B. An approach to the prevention of anxiety-related disorders based on evolutionary medicine. Prev Med. 2005; 40(6): 904–9.
  195. Price JS. Evolutionary aspects of anxiety disorders. Dialogues in Clinical Neuroscience. 2003; 5(3): 223–236.
  196. Watson JB, Rayner R. Conditioned emotional reactions. 1920. Am Psychol. 2000; 55(3): 313–7.
  197. Beck, H. P., Levinson, S., & Irons, G. (2009). "Finding Little Albert: A journey to John B. Watson's infant laboratory". American Psychologist, 64, 7.
  198. Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry. 2009; 66(12): 1361–72.
  199. Adolphs R, Tranel D, Hamann S, et al. Recognition of facial emotion in nine individuals with bilateral amygdala damage. Neuropsychologia. 1999; 37(10): 1111–7.
  200. Haygarth, John. (1800). Of the imagination, as a cause and as a cure of disorders of the body; exemplified by fictitious tractors, and epidemical convulsions. Read to the Literary and Philosophical Society of Bath. By John Haygarth, M.D. … Bath: printed by R. Cruttwell; and sold by Cadell and Davies, London.
  201. Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry. 2003; 64 Suppl 3: 21–7.
  202. Stein MB, Goin MK, Pollack MH, Roy-Byrne P, Sareen J, Simon NM, et al. Practice guideline for the treatment of patients with panic disorder. Arlington, VA: American Psychiatric Association, 2009.
  203. Association, American Psychiatric (2013). Diagnostic and statistical manual of mental disorders: DSM-5. (5th ed.). Washington, D.C.: American Psychiatric Association. p. 222.
  204. Heinze HJ, Mangun GR, Burchert W, et al. Combined spatial and temporal imaging of brain activity during visual selective attention in humans. Nature. 1994; 372(6506): 543–6.
  205. Bateson M, Brilot B, Nettle D. Anxiety: an evolutionary approach. Can J Psychiatry. 2011; 56(12): 707–15.
  206. Lundström JN, Olsson MJ. Functional Neuronal Processing of Human Body Odors. Vitamins and hormones. 2010; 83: 1–23. doi: 10.1016/S0083–6729(10)83001–8.
  207. Morgan E. The Scars of Evolution. Oxford University Press on Demand; 100–1, 1994.
  208. Depersonalization: A New Look at a Neglected Syndrome By Mauricio Sierra, p. 154.
  209. Favazza, A. (2012). Nonsuicidal self-injury: How categorization guides treatment. Current Psychiatry, 11, 21–26.
  210. Prodigal Genius: The Life of Nikola Tesla By John J. O'Neil, 293.
  211. Wilson, Bee, The Telegraph, "Alfred Hitchcock's complicated relationship with food," (http://www.telegraph.co.uk/journalists/bee-wilson/9818987/Alfred-Hitchcocks-complicated-relationship-with-food.html), March 8, 2016.
  212. Salvador Dal', Or the Art of Spitting on Your Mother's Portrait By Carlos Rojas, p. 46.
  213. Rapee RM. Family factors in the development and management of anxiety disorders. Clin Child Fam Psychol Rev. 2012; 15 (1): 69–80.
  214. Kendler K, Karkowski L, Prescott C (1999). "Fears and phobias: reliability and heritability". Psychological Medicine 29 (3): 539–53.
  215. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM–IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593–602.
  216. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM–IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593–602.
  217. Брайсон Б. Краткая история почти всего на свете. — М.: АСТ, 2016.
  218. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006; 63(4): 415.
  219. Yardley L, Britton J, Lear S, Bird J, Luxon LM. Relationship between balance system function and agoraphobic avoidance. Behav Res Ther. 1995; 33(4): 435–9.
  220. Jacob RG, Furman JM, Durrant JD, Turner SM. Panic, agoraphobia, and vestibular dysfunction. Am J Psychiatry. 1996; 153(4): 503–12.
  221. http://neilhilborn.tumblr.com/post/56192842620/buttonpoetry-neil-hilborn-ocd-rustbelt
  222. Association, American Psychiatric (2013). Diagnostic and statistical manual of mental disorders: DSM-5. (5th ed.). Washington, D.C.: American Psychiatric Association. p. 237.
  223. Fitzgerald KD, Welsh RC, Stern ER, et al. Developmental alterations of frontal-striatal-thalamic connectivity in obsessive compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2011; 50(9): 938–948.e3. doi: 10.1016/j.jaac.2011.06.011.
  224. Ahmari SE, Spellman T, Douglass NL, et al. Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science. 2013; 340(6137): 1234–9.
  225. Miller JA, Research Update BioScience. Vol. 42, No. 4 (Apr., 1992), pp. 257–261.
  226. Einstein DA, Menzies RG. Role of magical thinking in obsessive-compulsive symptoms in an undergraduate sample. Depress Anxiety. 2004; 19(3): 174–9.
  227. Shin LM, Shin PS, Heckers S, et al. Hippocampal function in posttraumatic stress disorder. Hippocampus. 2004; 14(3): 292–300.
  228. Skelton K, Ressler KJ, Norrholm SD, Jovanovic T, Bradley-davino B. PTSD and gene variants: new pathways and new thinking. Neuropharmacology. 2012; 62(2): 628–37.
  229. Van der kolk B. Posttraumatic stress disorder and the nature of trauma. Dialogues Clin Neurosci. 2000; 2(1): 7–22.
  230. Hirschfeld RMA. The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care. Primary Care Companion to The Journal of Clinical Psychiatry. 2001; 3(6): 244–254.
  231. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. Major depression and generalized anxiety disorder. Same genes, (partly) different environments? Arch Gen Psychiatry. 1992; 49(9): 716–22.
  232. Allgulander C, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003; 8(8 Suppl 1): 53–61.
  233. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord. 2000; 59(2): 119–26.
  234. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry. 2013; 12(2): 137–48.
  235. Otte C. Cognitive behavioral therapy in anxiety disorders: current state of the evidence. Dialogues in Clinical Neuroscience. 2011; 13(4): 413–421.
  236. Clapp P, Bhave SV, Hoffman PL. How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective. Alcohol Res Health. 2008; 31(4): 310–39.
  237. Davies M. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. Journal of Psychiatry and Neuroscience. 2003; 28(4): 263–274.
  238. Smith JP, Randall CL. Anxiety and alcohol use disorders: comorbidity and treatment considerations. Alcohol Res. 2012; 34(4): 414–31.
  239. McGovern TF, White WL. Alcohol Problems in the United States, Twenty Years of Treatment Perspective. Haworth Press; 2002. 5–40.
  240. Somnath Banerjee (2012). ADHD in Children and Adolescents: A Good Practice Guidance, Current Directions in ADHD and Its Treatment, Dr. Jill M. Norvilitis (Ed.).
  241. Ratey NA. The Disorganized Mind, Coaching Your ADHD Brain to Take Control of Your Time, Tasks, and Talents. St. Martin's Press, 2008.
  242. Hodgkins P, Arnold LE, Shaw M, et al. A Systematic Review of Global Publication Trends Regarding Long-Term Outcomes of ADHD. Frontiers in Psychiatry. 2011; 2: 84.
  243. Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit hyperactivity disorder. Attention Deficit and Hyperactivity Disorders. 2010; 2(4): 241–255.
  244. Ratey NA. The Disorganized Mind, Coaching Your ADHD Brain to Take Control of Your Time, Tasks, and Talents. St. Martin's Press, 2008.
  245. Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit hyperactivity disorder. Attention Deficit and Hyperactivity Disorders. 2010; 2(4): 241–255.
  246. Strohl MP. Bradley's Benzedrine Studies on Children with Behavioral Disorders. The Yale Journal of Biology and Medicine. 2011; 84(1): 27–33.
  247. Myers RL. The 100 Most Important Chemical Compounds, A Reference Guide. ABC–CLIO; 2007: 178–80.
  248. Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L. Financial ties between DSM–IV panel members and the pharmaceutical industry. Psychother Psychosom. 2006;75(3): 154–60.
  249. Americans With Disabilities Act of 1990, Pub. L. No. 101–336, 104 Stat. 328 (1990).
  250. Kessler, R.C., Adler, L., Ames, M., Demler, O., Faraone, S., Hiripi, E., Howes, M.J., Jin, R., Secnik, K., Spencer, T., Ustun, T.B., Walters, E.E. (2005). The World Health Organization Adult ADHD Self-Report Scale (ASRS). Psychological Medicine, 35(2), 245–25.
  251. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010; 10: 67.
  252. Arria AM, Wish ED. Nonmedical Use of Prescription Stimulants Among Students. Pediatric annals. 2006; 35(8): 565–571.
  253. Garnier-Dykstra LM, Caldeira KM, Vincent KB, O'Grady KE, Arria AM. Nonmedical use of prescription stimulants during college: Four-year trends in exposure opportunity, use, motives, and sources. Journal of American College Health: J of ACH. 2012; 60(3): 226–234.
  254. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000; 10(4): 311–20.
  255. Faraone SV. Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. P T. 2009; 34(12): 678–94.
  256. Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature. Prim Care Companion CNS Disord. 2014; 16(3).
  257. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009; 126(1): 51–90.
  258. Mccarthy H, Skokauskas N, Mulligan A, et al. Attention network hypoconnectivity with default and affective network hyperconnectivity in adults diagnosed with attention-deficit/hyperactivity disorder in childhood. JAMA Psychiatry. 2013; 70(12): 1329–37.
  259. Safer DJ, Krager JM. Treatment of Attention-Deficit Hyperactivity Disorder-Reply. JAMA. 1993; 269(18): 2369.
  260. Maraini D, Dacia Maraini Intervista Giorgio Antonucci. La Stampa, 26.7., 29 e 30.12.'78.
  261. Moffitt T, Melchior M. Why does the worldwide prevalence of childhood attention deficit hyperactivity disorder matter? The American Journal of Psychiatry. 2007; 146(6): 856–858. doi: 10.1176/appi.ajp.164.6.856.
  262. Shaw, P., Malek, M., Watson, B., Greenstein, D., de Rossi, P., & Sharp, W. (2013). Trajectories of Cerebral Cortical Development in Childhood and Adolescence and Adult Attention-Deficit/Hyperactivity Disorder, Biological Psychiatry, 74, 599–606.
  263. Sripada CS, Kessler D, Angstadt M. Lag in maturation of the brain's intrinsic functional architecture in attention-deficit/hyperactivity disorder. Proc Natl Acad Sci USA. 2014; 111(39): 14259–64.
  264. Volkow ND, Wang G-J, Newcorn JH, et al. Motivation Deficit in ADHD is Associated with Dysfunction of the Dopamine Reward Pathway. Molecular psychiatry. 2011;16(11): 1147–1154. doi: 10.1038/mp.2010.97.
  265. Голдберг Э. Управляющий мозг: Лобные доли, лидерство и цивилизация. — М.: Смысл, 2003.
  266. Archer D. The ADHD Advantage, What You Thought Was a Diagnosis May Be Your Greatest Strength. Hudson Street Press; 2015.
  267. Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry. 2002; 41 (4): 378–85.
  268. Ibid.
  269. Hartmann T. Attention Deficit Disorder, A Different Perception. Underwood Books; 1997.
  270. Archer D. The ADHD Advantage, What You Thought Was a Diagnosis May Be Your Greatest Strength. Hudson Street Press; 2015.
  271. Gilman L, Career Advice from the Corner Office: Famous People with ADHD, ADDitude, 2005 Dec-Jan.
  272. Archer D. The ADHD Advantage, What You Thought Was a Diagnosis May Be Your Greatest Strength. Hudson Street Press; 2015.
  273. World Health Organization (2012). Pharmacological and nonpharmacological interventions for children with attention-deficit hyperactivity disorder (ADHD). Geneva: WHO.
  274. Philipsen A, Richter H, Peters J, et al. Structured group psychotherapy in adults with attention deficit hyperactivity disorder: results of an open multicentre study. J Nerv Ment Dis. 2007; 195(12): 1013–9.
  275. Weiss M, Murray C, Wasdell M, Greenfield B, Giles L, Hechtman L. A randomized controlled trial of CBT therapy for adults with ADHD with and without medication. BMC Psychiatry. 2012; 12:30. doi: 10.1186/1471–244X-12–30.
  276. Morton WA, Stockton GG. Methylphenidate Abuse and Psychiatric Side Effects. Primary Care Companion to The Journal of Clinical Psychiatry. 2000; 2(5): 159–164.
  277. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the Efficacy of Medications for ADHD Using Meta-analysis. Medscape General Medicine. 2006; 8(4): 4.
  278. Safren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005; 43(7): 831–42.
  279. Зиновьева А. Космический пришелец по имени Иван // Московский комсомолец. — 2013. — 5 июля (№ 26272).
  280. Schechter MD, Timmons GD. Objectively measured hyperactivity — II. Caffeine and amphetamine effects. J Clin Pharmacol. 1985; 25(4): 276–80.
  281. Arnold LE, Christopher J, Huestis R, Smeltzer DJ. Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis. Arch Gen Psychiatry. 1978; 35(4): 463–73.
  282. Archer D. The ADHD Advantage, What You Thought Was a Diagnosis May Be Your Greatest Strength. Hudson Street Press; 2015.
  283. Wing L. The history of ideas on autism: Legends, myths and reality. Autism. 1997; 1: 13–23.
  284. Miles, M. "Martin Luther and Childhood Disability in 16th Century Germany: What Did He Write? What Did He Say?" Journal of Religion, Disability, and Health 5, no. 4: 5–36.
  285. Houston R, Frith U. Autism in History, The Case of Hugh Blair of Borgue. Wiley-Blackwell; 2000.
  286. Rapaport, David, (1951). Organization and pathology of thought: Selected sources., (pp. 399–437). New York, NY, US: Columbia University Press, xviii, 786 pp.
  287. Baron-Cohen S, Klin A. What's so special about Asperger Syndrome?. Brain Cogn. 2006; 61(1): 1–4.
  288. Wing L. Asperger's syndrome: a clinical account. Psychol Med. 1981; 11(1): 115–29.
  289. Silberman S. NeuroTribes, The Legacy of Autism and How to Think Smarter About People Who Think Differently. 2016.
  290. Feinstein A. A History of Autism, Conversations with the Pioneers. Wiley-Blackwell; 2010.
  291. Yu KK, Cheung C, Chua SE, Mcalonan GM. Can Asperger syndrome be distinguished from autism? An anatomic likelihood meta-analysis of MRI studies. J Psychiatry Neurosci. 2011; 36(6): 412–21.
  292. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013; 12(2): 92–98. doi: 10.1002/wps.20050.
  293. Peek K., Inspiration for 'Rain Man,' Dies at 58, The New York Times, December 27, 2009, A30.
  294. Treffert DA. The savant syndrome and autistic disorder. CNS Spectr. 1999; 4(12): 57–60.
  295. Klin A. [Autism and Asperger syndrome: an overview]. Rev Bras Psiquiatr. 2006; 28 Suppl 1: S3–11.
  296. Klin A. [Autism and Asperger syndrome: an overview]. Rev Bras Psiquiatr. 2006; 28 Suppl 1: S3–11.
  297. Roy M, Dillo W, Emrich HM, Ohlmeier MD. Asperger's syndrome in adulthood. Dtsch Arztebl Int. 2009; 106(5): 59–64.
  298. Rogers SJ, Ozonoff S. Annotation: what do we know about sensory dysfunction in autism? A critical review of the empirical evidence. J Child Psychol Psychiatry. 2005; 46(12): 1255–68.
  299. Allely CS. Pain Sensitivity and Observer Perception of Pain in Individuals with Autistic Spectrum Disorder. The Scientific World Journal. 2013; 2013: 916178.
  300. Green D, Baird G, Barnett AL, Henderson L, Huber J, Henderson SE. The severity and nature of motor impairment in Asperger's syndrome: a comparison with specific developmental disorder of motor function. J Child Psychol Psychiatry. 2002; 43(5): 655–68.
  301. Blakemore SJ, Tavassoli T, Calò S, et al. Tactile sensitivity in Asperger syndrome. Brain Cogn. 2006; 61(1): 5–13.
  302. Lugnegård T, Hallerbäck MU, Gillberg C. Psychiatric comorbidity in young adults with a clinical diagnosis of Asperger syndrome. Res Dev Disabil. 2011; 32(5): 1910–7.
  303. Miles JH, McCathren RB, Stichter J, et al. Autism Spectrum Disorders. 2003 Aug 27 [Updated 2010 Apr 13]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2016. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1442/
  304. South M, Ozonoff S, Mcmahon WM. Repetitive behavior profiles in Asperger syndrome and high-functioning autism. J Autism Dev Disord. 2005; 35(2): 145–58.
  305. Boyd BA, McDonough SG, Bodfish JW. Evidence-Based Behavioral Interventions for Repetitive Behaviors in Autism. Journal of autism and developmental disorders. 2012; 42(6): 1236–1248.
  306. Newman SS, Ghaziuddin M. Violent crime in Asperger syndrome: the role of psychiatric comorbidity. J Autism Dev Disord. 2008; 38(10): 1848–52.
  307. Mouridsen SE, Rich B, Isager T, Nedergaard NJ. Pervasive developmental disorders and criminal behaviour: a case control study. Int J Offender Ther Comp Criminol. 2008; 52(2): 196–205.
  308. Mazefsky CA, Herrington J, Siegel M, et al. The Role of Emotion Regulation in Autism Spectrum Disorder RH: Emotion Regulation in ASD. Journal of the American Academy of Child and Adolescent Psychiatry. 2013; 52(7): 679–688. doi: 10.1016/j.jaac.2013.05.006.
  309. Ghaziuddin M, Tsai L, Ghaziuddin N. Brief report: violence in Asperger syndrome, a critique. J Autism Dev Disord. 1991; 21(3): 349–54.
  310. Castillo M., Asperger's not likely to make people violent, experts emphasize, CBS News, December 17, 2012.
  311. Baez S, Rattazzi A, Gonzalez-gadea ML, et al. Integrating intention and context: assessing social cognition in adults with Asperger syndrome. Front Hum Neurosci. 2012; 6: 302.
  312. Zalla T, Sav AM, Stopin A, Ahade S, Leboyer M. Faux pas detection and intentional action in Asperger Syndrome. A replication on a French sample. J Autism Dev Disord. 2009; 39(2): 373–82.
  313. Henry O'Connell and Michael Fitzgerald (2003). Did Alan Turing have Asperger's syndrome?. Irish Journal of Psychological Medicine, 20, pp. 28–31.
  314. Decety J, Moriguchi Y. The empathic brain and its dysfunction in psychiatric populations: implications for intervention across different clinical conditions. Biopsychosoc Med. 2007; 1: 22.
  315. Raftery B., How Dan Harmon Drives Himself Crazy Making Community, Wired, 09.2011.
  316. Grove R, Baillie A, Allison C, Baron-Cohen S, Hoekstra RA. The latent structure of cognitive and emotional empathy in individuals with autism, first-degree relatives and typical individuals. Molecular Autism. 2014; 5: 42. doi: 10.1186/2040–2392–5–42.
  317. Mazza M, Pino MC, Mariano M, et al. Affective and cognitive empathy in adolescents with autism spectrum disorder. Front Hum Neurosci. 2014; 8: 791.
  318. Mcintosh DN, Reichmann-decker A, Winkielman P, Wilbarger JL. When the social mirror breaks: deficits in automatic, but not voluntary, mimicry of emotional facial expressions in autism. Dev Sci. 2006; 9(3): 295–302.
  319. Markram H, Rinaldi T, Markram K. The Intense World Syndrome — an Alternative Hypothesis for Autism. Frontiers in Neuroscience. 2007; 1(1): 77–96. doi: 10.3389/neuro.01.1.1.006.2007.
  320. Hayashi M, Kato M, Igarashi K, Kashima H. Superior fluid intelligence in children with Asperger's disorder. Brain Cogn. 2008; 66(3): 306–10.
  321. Baron-Cohen S, Golan O, Ashwin E. Can emotion recognition be taught to children with autism spectrum conditions? Philosophical Transactions of the Royal Society B: Biological Sciences. 2009; 364(1535): 3567–3574.
  322. Segar M. Faire face, guide de survie à l'intention des personnes atteintes du syndrome d'Asperger. 1998.
  323. http://www.aspergers.ru/node/94
  324. Willingham D., 'Wall Street' Actress Daryl Hannah Is An Autistic Woman, Forbes, 9.29.2013.
  325. Shattuck PT, Narendorf SC, Cooper B, Sterzing PR, Wagner M, Taylor JL. Postsecondary education and employment among youth with an autism spectrum disorder. Pediatrics. 2012; 129(6): 1042–9.
  326. James I. Singular scientists. Journal of the Royal Society of Medicine. 2003; 96(1): 36–39.
  327. Ruthsatz, J., & Urbach, J. B., Child prodigy: A novel cognitive profile places elevated general intelligence, exceptional working memory and attention to detail… Intelligence (2012).
  328. Baron-Cohen S, Bolton P, Wheelwright S, Scahill V, Short L, Mead G, Smith A. Does autism occur more often in families of physicists, engineers, and mathematicians? Autism. 1998; 2 (3): 296–301.
  329. Clarke T-K. et al. Common polygenic risk for autism spectrum disorder (ASD) is associated with cognitive ability in the general population. Molecular Psychiatry. 2015. March 10.
  330. Frith U. Emanuel Miller lecture: confusions and controversies about Asperger syndrome. J Child Psychol Psychiatry. 2004; 45(4): 672–86.
  331. Grove R, Roth I, Hoekstra RA. The motivation for special interests in individuals with autism and controls: Development and validation of the special interest motivation scale. Autism Res. 2015.
  332. Prior M, Ozonoff S (2007). "Psychological factors in autism". In Volkmar FR. Autism and Pervasive Developmental Disorders (2nd ed.). Cambridge University Press. pp. 69–128.
  333. http://youtu.be / i_yJTCDU4uE
  334. Freitag CM. The genetics of autistic disorders and its clinical relevance: a review of the literature. Mol Psychiatry. 2007; 12(1): 2–22.
  335. Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 2006; 29(7): 349–58.
  336. Courchesne E, Mouton PR, Calhoun ME, et al. Neuron Number and Size in Prefrontal Cortex of Children With Autism. JAMA. 2011; 306(18): 2001–2010.
  337. Kanold PO. Subplate neurons: crucial regulators of cortical development and plasticity. Front Neuroanat. 2009; 3: 16.
  338. Hadjikhani N, Joseph RM, Snyder J, Tager-flusberg H. Anatomical differences in the mirror neuron system and social cognition network in autism. Cereb Cortex. 2006; 16(9): 1276–82.
  339. Cheng Y, Yang CY, Lin CP, Lee PL, Decety J. The perception of pain in others suppresses somatosensory oscillations: a magnetoencephalography study. Neuroimage. 2008; 40(4): 1833–40.
  340. Lamm C, Batson CD, Decety J. The neural substrate of human empathy: effects of perspective-taking and cognitive appraisal. J Cogn Neurosci. 2007; 19(1): 42–58.
  341. Botvinick M, Jha AP, Bylsma LM, Fabian SA, Solomon PE, Prkachin KM. Viewing facial expressions of pain engages cortical areas involved in the direct experience of pain. Neuroimage. 2005; 25(1): 312–9.
  342. Jabbi M, Swart M, Keysers C. Empathy for positive and negative emotions in the gustatory cortex. Neuroimage. 2007; 34(4): 1744–53.
  343. Hamilton AF. Goals, intentions and mental states: challenges for theories of autism. J Child Psychol Psychiatry. 2009; 50(8): 881–92.
  344. Dinstein I, Thomas C, Humphreys K, Minshew N, Behrmann M, Heeger DJ. Normal movement-selectivity in autism. Neuron. 2010; 66(3): 461–469. doi: 10.1016/j.neuron.2010.03.034.
  345. Ramachandran VS, Oberman LM. Broken mirrors: a theory of autism. Sci Am. 2006; 295(5): 62–9.
  346. Baron-Cohen S, Leslie AM, Frith U. Does the autistic child have a "theory of mind"?. Cognition. 1985; 21(1): 37–46.
  347. Ruffman T, Garnham W, Rideout P. Social understanding in autism: eye gaze as a measure of core insights. J Child Psychol Psychiatry. 2001; 42(8): 1083–94.
  348. RETRACTED: Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351(9103):637–41.
  349. Fraser M., Anti-MMR doctor is forced out, The Telegraph, 02 Dec 2001.
  350. Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. MP, Mol Pathol. 2002; 55(2): 84–90.
  351. Goldacre M., The MMR hoax, The Guardian, 30 August 2008.
  352. Health and Social Care Information Centre, NHS Immunisation Statistics England 2012–13, 26 September 2013.
  353. Deer B., MMR doctor Andrew Wakefield fixed data on autism, The Sunday Times, 8 February 2009.
  354. Horton R. The lessons of MMR. Lancet. 2004; 363 (9411): 747–9.
  355. Miriam Falco, Vaccine study's author held related patent, medical journal reports, CNN, January 12, 2011.
  356. RETRACTED: Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998; 351(9103): 637–41.
  357. Flaherty DK. The vaccine-autism connection: a public health crisis caused by unethical medical practices and fraudulent science. Ann Pharmacother. 2011; 45(10): 1302–4.
  358. Health and Social Care Information Centre, NHS Immunisation Statistics England 2012–13, 26, September 2013.
  359. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014; 32(29): 3623–9.
  360. Seida JK, Ospina MB, Karkhaneh M, Hartling L, Smith V, Clark B. Systematic reviews of psychosocial interventions for autism: an umbrella review. Dev Med Child Neurol. 2009; 51(2): 95–104.
  361. Eikeseth S. Outcome of comprehensive psycho-educational interventions for young children with autism. Res Dev Disabil. 2009; 30(1): 158–78.
  362. Buitelaar JK. Why have drug treatments been so disappointing?. Novartis Found Symp. 2003; 251: 235–44.
  363. Nicholas Lofthouse, Robert Hendren, Elizabeth Hurt, L. Eugene Arnold, and Eric Butter, "A Review of Complementary and Alternative Treatments for Autism Spectrum Disorders," Autism Research and Treatment, vol. 2012, 2012.
  364. Tonya N. Davis et al., "Chelation Treatment for Autism Spectrum Disorders: A Systematic Review," Research in Autism Spectrum Disorders 7 (January 2013): 49–55.
  365. Tonya N. Davis et al., "Chelation Treatment for Autism Spectrum Disorders: A Systematic Review," Research in Autism Spectrum Disorders 7 (January 2013): 49–55.
  366. Myles, B. S., Huggins, A., Rome-Lake, M., Hagiwara, T., Barnhill, G. P., & Griswold, D. E. (2003). Written Language Profile of Children and Youth with Asperger Syndrome: From Research to Practice. Education and Training in Developmental Disabilities, 38(4), 362–369.
  367. Blume H., Autistics, freed from face-to-face encounters, are communicating in cyberspace. The New York Times, June 30, 1997.
  368. Saner E., 'It is not a disease, it is a way of life', The Guardian, 7 August 2007.
  369. https://www.autismspeaks.org/liub
  370. General Assembly resolution 62/139, World Autism Awareness Day, A/RES/62/139 (21 January 2008), available from undocs.org/A/RES/62/139.
  371. Morel BA. Traité des maladies mentales. [Treatise on mental diseases]. Paris, France: Masson; 1860.
  372. Berrios GE. Phthisical insanity by T. S. Clouston. Hist Psychiatry. 2005; 16(Pt 4 (no 64)): 473–9.
  373. Hecker E. Die Hebephrenie: ein Beitrag zur klinischen Psychiatrie. [Hebephrenia: a contribution to clinical psychiatry] Archiv für pathologische Anatomie und für klinische Medizin. 1871.
  374. Kahlbaum KL. Die Gruppierung der psychischen Krankheiten und die Einteilung der Seelenstörungen. [The Grouping of Psychiatric Diseases and the Classification of Mental Disturbances]. Danzig, Germany: Kafemann; 1863.
  375. Kraepelin E. Psychiatrie. 6 Auflage. Leipzig, Austria: Barth 1899. English translation by Metoui H, Ayed S: Psychiatry, A Textbook for Students and Physicians.
  376. Waters FA, Badcock JC, Dragovic´ M, Jablensky A. Neuropsychological functioning in schizophrenia patients with first-rank (passivity) symptoms. Psychopathology. 2009; 42(1): 47–58.
  377. Wilkinson G. Political dissent and "sluggish" schizophrenia in the Soviet Union. British Medical Journal (Clinical research ed). 1986; 293(6548): 641–642.
  378. Bonnie RJ. Political abuse of psychiatry in the Soviet Union and in China: complexities and controversies. J Am Acad Psychiatry Law. 2002; 30(1): 136–44.
  379. World Health Organization. (1992). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.
  380. Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987; 151: 145–51.
  381. Johnstone EC, Frith CD. Validation of three dimensions of schizophrenic symptoms in a large unselected sample of patients. Psychol Med. 1996; 26(4): 669–79.
  382. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch Gen Psychiatry. 1995; 52(5): 352–60.
  383. World Health Organization. (1992). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.
  384. Lindström, E et al., The ICD-10 and DSM–IV diagnostic criteria and the prevalence of schizophrenia, European Psychiatry, (1997). Volume 12, Issue 5, 217–223.
  385. Upthegrove R, Birchwood M, Ross K, Brunett K, Mccollum R, Jones L. The evolution of depression and suicidality in first episode psychosis. Acta Psychiatr Scand. 2010; 122(3): 211–8.
  386. Sham PC, Maclean CJ, Kendler KS. A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr Scand. 1994; 89(2): 135–41.
  387. Brugha T, Singleton N, Meltzer H, et al. Psychosis in the community and in prisons: a report from the British National Survey of psychiatric morbidity. Am J Psychiatry. 2005; 162(4): 774–80.
  388. Ostling S, Skoog I. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry. 2002; 59(1): 53–9.
  389. Лаувенг А. Завтра я всегда бывала львом. — М.: Бахрах-М, 2012.
  390. Trémeau F, Antonius D, Cacioppo JT, et al. In support of Bleuler: objective evidence for increased affective ambivalence in schizophrenia based upon evocative testing. Schizophr Res. 2009; 107(2–3): 223–31.
  391. De Clerambault, Psychoses a base d'automatisme (1925), La Psychiatrie, 1994: 511.
  392. Kiran C, Chaudhury S. Understanding delusions. Industrial Psychiatry Journal. 2009; 18(1): 3–18.
  393. О'Брайен Б. Необыкновенное путешествие в безумие и обратно: Операторы и вещи. — М.: Класс, 1996.
  394. Byrne P. Managing the acute psychotic episode. BMJ: British Medical Journal. 2007; 334(7595): 686–692.
  395. Van rensburg AB, Olorunju S. Diagnosis and treatment of schizophrenia in a general hospital based acute psychiatric ward. Afr J Psychiatry (Johannesbg). 2010; 13(3): 204–10.
  396. Surviving Schizophrenia: A Manual for Families, Patients, and Providers (5th Edition) by E. Fuller Torrey (Author), Publisher: Quill; 5th edition (April 1, 2006).
  397. Mitchison A., Kim Noble: The woman with 100 personalities, The Guardian, 30 September 2011.
  398. Nathan PE, Gorman JM. A Guide to Treatments that Work. Oxford University Press, USA; 2007: 463–5.
  399. Beidel DC, Frueh BC, Hersen M. Adult Psychopathology and Diagnosis. John Wiley & Sons; 2014.
  400. Korol S. Familial and social support as protective factors against the development of dissociative identity disorder. J Trauma Dissociation. 2008; 9(2): 249–67.
  401. Gillig PM. Dissociative identity disorder: a controversial diagnosis. Psychiatry (Edgmont). 2009; 6(3): 24–9.
  402. Galvin JE, Sadowsky CH. Practical guidelines for the recognition and diagnosis of dementia. J Am Board Fam Med. 2012; 25(3): 367–82.
  403. Burns A, Iliffe S. Dementia. BMJ. 2009; 338: b75.
  404. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007; 6(11): 994–1003.
  405. O'donovan MC, Williams NM, Owen MJ. Recent advances in the genetics of schizophrenia. Hum Mol Genet. 2003; 12 Spec No 2: R125–33.
  406. Torrey EF. Surviving Schizophrenia, 6th Edition, A Family Manual. Harper Perennial; 2013: 135.
  407. Van os J, Kapur S. Schizophrenia. Lancet. 2009; 374(9690): 635–45.
  408. Cardno AG, Marshall EJ, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry. 1999; 56(2): 162–8.
  409. Kendler KS, Mcguire M, Gruenberg AM, O'Hare A, Spellman M, Walsh D. The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry. 1993; 50(7): 527–40.
  410. O'Donovan MC, Williams NM, Owen MJ. Recent advances in the genetics of schizophrenia. Hum Mol Genet. 2003; 12 Spec No 2: R125–33.
  411. Torrey EF, Yolken RH. Psychiatric Genocide: Nazi Attempts to Eradicate Schizophrenia. Schizophrenia Bulletin. 2010; 36(1): 26–32.
  412. Crow TJ. Schizophrenia as the price that homo sapiens pays for language: a resolution of the central paradox in the origin of the species. Brain Res Brain Res Rev. 2000; 31(2–3): 118–29.
  413. Burns JK. An evolutionary theory of schizophrenia: cortical connectivity, metarepresentation, and the social brain. Behav Brain Sci. 2004; 27(6): 831–55.
  414. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III — the final common pathway. Schizophr Bull. 2009; 35(3): 549–62.
  415. Carlsson A., Carlsson ML. Dopaminergic stabilisers. Adv Schizophrenia and Clin Psychiatry. 2005; 1: 118–128.
  416. Da silva alves F, Figee M, Van amelsvoort T, Veltman D, De haan L. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol Bull. 2008; 41(1): 121–32.
  417. Pogarell O, Koch W, Karch S, et al. Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry, 2012; 45 Suppl 1: S36–41.
  418. Mechri A, Saoud M, Khiari G, D'amato T, Dalery J, Gaha L. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine]. Encephale. 2001; 27(1): 53–9.
  419. Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr Res. 2005; 73(2–3): 147–52.
  420. Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012; 38(5): 920–6.
  421. Richard A, Churan J, Whitford V, O'driscoll GA, Titone D, Pack CC. Perisaccadic perception of visual space in people with schizophrenia. J Neurosci. 2014; 34(14):4760–5.
  422. Bateson, G., Jackson, D. D., Haley, J. & Weakland, J. (1956), Towards a Theory of Schizophrenia. in Behavioral Science, Vol 1, 251–264.
  423. Large M, Smith G, Nielssen O. The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis. Schizophr Res. 2009; 112(1–3):123–9.
  424. Phelan, J. C., Link, B. G., Stueve, A., & Pescosolido, B. A. (2000). Public Conceptions of Mental Illness in 1950 and 1996: What Is Mental Illness and Is It to be Feared? Journal of Health and Social Behavior, 41(2), 188–207.
  425. Pronin, E., Perception and misperception of bias in human judgment, (2007) Trends in Cognitive Sciences, Volume 11, Issue 1, 37–43.
  426. Walsh E, Fahy T. Violence in society: Contribution of mental illness is low. BMJ: British Medical Journal. 2002; 325(7363): 507–508.
  427. Burton N. The Meaning of Madness. Oxford: Acheron Press, 2009; 2008.
  428. Kaufman SB, How Is Creativity Differentially Related to Schizophrenia and Autism? Scientific American, June 10, 2015
  429. Marquis DM. In Search of Buddy Bolden, First Man of Jazz. LSU Press; 2005.
  430. Jobe TH, Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry. 2005; 50(14): 892–900.
  431. Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001; 178: 506–17.
  432. Saks ER., Diary of a High-Functioning Person with Schizophrenia, Scientific American, December 29, 2009.
  433. Wiersma D, Wanderling J, Dragomirecka E, et al. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med. 2000; 30 (5): 1155–67.
  434. Ruhrmann S, Schultze-lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010; 67(3): 241–51.
  435. Doroshow DB. Performing a cure for schizophrenia: insulin coma therapy on the wards. J Hist Med Allied Sci. 2007;62 (2):213–43.
  436. Raz M. The painless brain: lobotomy, psychiatry, and the treatment of chronic pain and terminal illness. Perspect Biol Med. 2009; 52(4): 555–65.
  437. Epstein NN. Artificial Fever as a Therapeutic Procedure. Cal West Med. 1936; 44(5): 357–8.
  438. "The Nobel Prize in Physiology or Medicine 1927". Nobelprize.org. Nobel Media AB2014. Web. 14 Mar 2016. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1927/
  439. Hamon, Paraire, Velluz. [Effect of R. P. 4560 on maniacal agitation]. Ann Med Psychol (Paris). 1952; 110: 331–5.
  440. Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatric Disease and Treatment. 2007; 3(4): 495–500.
  441. Ban TA. Pharmacotherapy of mental illness — a historical analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25(4): 709–27.
  442. Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues in Clinical Neuroscience. 2006; 8(1):137–142.
  443. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010; 81(5): 617–22.
  444. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007; 18(1): 39–60.
  445. Brisch R, Saniotis A, Wolf R, et al. The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue. Frontiers in Psychiatry. 2014; 5:47. doi: 10.3389/fpsyt.2014.00047.
  446. Xiberas X, Martinot JL, Mallet L, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry. 2001; 179: 503–8.
  447. Хаэр Р. Лишенные совести: Пугающий мир психопатов. — М.: Вильямс, 2014.
  448. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.
  449. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.). Arlington, VA: American Psychiatric Publishing.
  450. Ющенко А. И. Основы учений о преступнике, душевнобольном и психологии нормального человека. Введение в курс судебной психопатологии. — СПб.: Издание К. Л. Риккера, 1913.
  451. Каннабих Ю. В. История психиатрии. — Л.: Государственное медицинское издательство, 1928.
  452. Буянин Д. Диспут о Канте закончился стрельбой в Ростове // РИА «Новости». 2013. 16 сентября.
  453. Bürgy M. The Concept of Psychosis: Historical and Phenomenological Aspects. Schizophrenia Bulletin. 2008; 34(6):1200–1210.
  454. Ferrero J. Lombroso's Criminal Man. — N.Y., 1919. — P. XIV.
  455. Goring C. The English Convict. — L., 1913. — P. 173.
  456. Cleckley, Hervey (1982). The Mask of Sanity. Revised Edition. Mosby Medical Library.
  457. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 3rd edition. Washington, DC American Psychiatric Association; 1980.
  458. Hare, R. D. (1980). A research scale for the assessment of psychopathy in criminal populations. Personality and Individual Differences, 1, 111–117.
  459. Хаэр Р. Лишенные совести: Пугающий мир психопатов. — М.: Виль­ямс, 2014.
  460. Moran P. The epidemiology of antisocial personality disorder. Soc Psychiatry Psychiatr Epidemiol. 1999; 34(5): 231–42.
  461. Хаэр Р. Лишенные совести: Пугающий мир психопатов. — М.: Вильямс, 2014.
  462. Antisocial Personality Disorder: Treatment, Management and Prevention. NICE Clinical Guidelines, No. 77. National Collaborating Centre for Mental Health (UK).Leicester (UK): British Psychological Society; 2010.
  463. Lilienfeld SO. Doctoral Dissertation. University of Minnesota; Minneapolis: 1990. Development and preliminary validation of a slf-report of psychopathic personality.
  464. Даттон К. Мудрость психопатов. — СПб.: Питер, 2014.
  465. McWilliams N. Psychoanalytic Diagnosis, Understanding Personality Structure in the Clinical Process. Guilford Press; 1994.
  466. Kent A. Kiehl, Peter F. Liddle, Andra M. Smith, Adrianna Mendrek, Bruce B. Forster and Robert D. Hare. Neural pathways involved in the processing of concrete and abstract words. Psychophysiology, 36 (1999).
  467. Thomas ST, Sociopaths Confirm: They're Great in Bed (But They Might Treat You Like a Houseplant), Vice, July 19, 2015.
  468. http://www.sociopathworld.com/
  469. Dutton DL. The cold reading technique. Experientia. 1988; 44(4): 326–32.
  470. Wheeler S, Book A, Costello K. Psychopathic Traits and Perceptions of Victim Vulnerability, Criminal Justice and Behavior Volume:36 Issue:6, June 2009: 635–48.
  471. Cleckley HM. The Mask of Sanity. Textbook Pub; 2003.
  472. Eysenck EJ, Personality and the Biosocial Model of Anti-Social and Criminal Behaviour, Biosocial Bases of Violence, Springer US, 1997: 21–37.
  473. Quay, Herbert C. 1965. Psychopathic personality as pathological stimulation seeking. American Journal of Psychiatry, 122, 180–183.
  474. Raine A, Fung AL, Portnoy J, Choy O, Spring VL. Low heart rate as a risk factor for child and adolescent proactive aggressive and impulsive psychopathic behavior. Aggress Behav. 2014; 40(4): 290–9.
  475. Raine A, Venables PH, Mednick SA. Low resting heart rate at age 3 years predisposes to aggression at age 11 years: evidence from the Mauritius Child Health Project. J Am Acad Child Adolesc Psychiatry. 1997; 36(10): 1457–64.
  476. Ortiz J, Raine A. Heart rate level and antisocial behavior in children and adolescents: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2004; 43(2): 154–62.
  477. From Craig, M., Catani, M., Deeley, Q., Latham, R., Daly, E., Kanaan, R., Picchioni, M., McGuire, P., Fahy, T., & Murphy, D. (2009). Altered connections on the road to psychopathy Molecular Psychiatry, 14 (10), 946–953 DOI: 10.1038/mp.2009.40.
  478. Koenigs M, Kruepke M, Newman JP. Economic decision-making in psychopathy: a comparison with ventromedial prefrontal lesion patients. Neuropsychologia. 2010; 48(7): 2198–204.
  479. McWilliams N. Psychoanalytic Diagnosis, Understanding Personality Structure in the Clinical Process. Guilford Press; 1994.
  480. Rothemund Y, Ziegler S, Hermann C, et al. Fear conditioning in psychopaths: event-related potentials and peripheral measures. Biol Psychol. 2012; 90(1): 50–9.
  481. Birbaumer N, Veit R, Lotze M, et al. Deficient fear conditioning in psychopathy: a functional magnetic resonance imaging study. Arch Gen Psychiatry. 2005; 62(7): 799–805.
  482. Hare RD. Detection threshold for electric shock in psychopaths. J Abnorm Psychol. 1968; 73(3): 268–72.
  483. Blair, R. J. R. (2010). Psychopathy, frustration, and the role of reactive aggression: The role of the ventromedial prefrontal cortex. British Journal of Psychology, 101, 383–399.
  484. Buckholtz JW, Treadway MT, Cowan RL, et al. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat Neurosci. 2010; 13(4): 419–21.
  485. Konnikova M, Stop Calling Sherlock a Sociopath! Thanks, a Psychologist, Criminal Element, Aug 8 2012, Available at: http://www.criminalelement.com/blogs/2012/08/stop-calling-sherlock-a-sociopath-psychologist-maria-konnikova. Accessed March 16, 2016.
  486. Craig, M., Catani, M., Deeley, Q., Latham, R., Daly, E., Kanaan, R., Picchioni, M., McGuire, P., Fahy, T., & Murphy, D. (2009). Altered connections on the road to psychopathy Molecular Psychiatry, 14 (10).
  487. Kevin M. Beavera, Matt DeLisib, Michael G. Vaughnc, J. C. Barnesa. Monoamine oxidase A genotype is associated with gang membership and weapon use.
  488. Caspi A et al, Role of Genotype in the Cycle of Violence in Maltreated Children, Science, 2002 (5582/297): 851–4
  489. Khalifa N, Duggan C, Stoffers J, et al. Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev. 2010; (8): CD007667.
  490. Harris Grant T, et al. Psychopathy and Violent Recidivism. Law & Hum Behav. 1991; 15: 625.
  491. http://www.worldsciencefestival.com/2011/09
    /moth_confessions_of_a_pro_social_psychopath/
  492. Morton RJ, Serial Murder: Multi-Disciplinary Perspectives for Investigators, National Ctr for the Analysis of Violent Crime (NCAVC), 2008.
  493. Hasler G, Hopwood CJ, Jacob GA, Brändle LS, Schulte-vels T. Patient-reported outcomes in borderline personality disorder. Dialogues Clin Neurosci. 2014; 16(2): 255–66.
  494. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author: 663–6.
  495. Cohen P. Child development and personality disorder. Psychiatr Clin North Am. 2008; 31(3): 477–93, vii.
  496. Zanarini MC, Frankenburg FR, Reich DB, et al. Biparental failure in the childhood experiences of borderline patients. J Pers Disord. 2000; 14(3): 264–73.
  497. Zanarini MC, Frankenburg FR. Pathways to the development of borderline personality disorder. J Pers Disord. 1997; 11(1): 93–104.
  498. Goldman SJ, D'angelo EJ, Demaso DR. Psychopathology in the families of children and adolescents with borderline personality disorder. Am J Psychiatry. 1993; 150(12): 1832–5.
  499. South SC, Turkheimer E, Oltmanns TF. Personality disorder symptoms and marital functioning. J Consult Clin Psychol. 2008; 76(5): 769–80.
  500. Coid J, Yang M, Tyrer P, Roberts A, Ullrich S. Prevalence and correlates of personality disorder in Great Britain. Br J Psychiatry. 2006; 188: 423–31.
  501. Samuels J, Eaton WW, Bienvenu OJ, Brown CH, Costa PT, Nestadt G. Prevalence and correlates of personality disorders in a community sample. Br J Psychiatry. 2002; 180: 536–42.
  502. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry. 2001; 58(6): 590–6.
  503. Grant BF, Chou SP, Goldstein RB, et al. Prevalence, correlates, disability, and comorbidity of DSM–IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008; 69(4): 533–45.
  504. Skodol AE, Gunderson JG, Mcglashan TH, et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. Am J Psychiatry. 2002; 159(2): 276–83.
  505. Oumaya M, Friedman S, Pham A, Abou abdallah T, Guelfi JD, Rouillon F. [Borderline personality disorder, self-mutilation and suicide: literature review]. Encephale. 2008; 34(5): 452–8.
  506. Bui E, Rodgers R, Chabrol H, Birmes P, Schmitt L. Is Anakin Skywalker suffering from borderline personality disorder? Psychiatry Res. 2011; 185(1–2): 299.
  507. Kreger R, Putting Darth Vader On The Couch, Psychology Today, Jun 2010.
  508. Torgersen S, Lygren S, Oien PA, et al. A twin study of personality disorders. Compr Psychiatry. 2000; 41(6): 416–25.
  509. Reichborn-kjennerud T, Czajkowski N, Neale MC, et al. Genetic and environmental influences on dimensional representations of DSM–IV cluster C personality disorders: a population-based multivariate twin study. Psychol Med. 2007; 37(5): 645–53.
  510. Gratz AC. The Borderline Personality Disorder: Everything You Need to Know about Living with Bpd (Large Print 16pt). ReadHowYouWant.com; 2010.
  511. Miller PM, Lisak D, Associations Between Childhood Abuse and Personality Disorder Symptoms in College Males J Interpers Violence June 1999, 14: 642–656.
  512. Cohen P. Child development and personality disorder. Psychiatr Clin North Am. 2008; 31(3): 477–93, vii.
  513. Zanarini MC, Frankenburg FR, Reich DB, et al. Biparental failure in the childhood experiences of borderline patients. J Pers Disord. 2000; 14(3): 264–73.
  514. Waters E, Merrick S, Treboux D, Crowell J, Albersheim L. Attachment security in infancy and early adulthood: a twenty-year longitudinal study. Child Dev. 2000; 71(3): 684–9.
  515. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274(5292): 1527–31.
  516. Rinne T, Westenberg HG, Den boer JA, Van den brink W. Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Biol Psychiatry. 2000; 47(6): 548–56.
  517. Herpertz SC, Dietrich TM, Wenning B, et al. Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biol Psychiatry. 2001; 50(4): 292–8.
  518. Gunderson JG, Sabo AN. The phenomenological and conceptual interface between borderline personality disorder and PTSD. Am J Psychiatry. 1993; 150(1): 19–27.
  519. Twenge JM, Gentile B, Dewall CN, Ma D, Lacefield K, Schurtz DR. Birth cohort increases in psychopathology among young Americans, 1938–2007: A cross-temporal meta-analysis of the MMPI. Clin Psychol Rev. 2010; 30(2): 145–54.
  520. Tebartz van elst L, Hesslinger B, Thiel T, et al. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry. 2003; 54(2): 163–71.
  521. Rausch J, Gäbel A, Nagy K, Kleindienst N, Herpertz SC, Bertsch K. Increased testosterone levels and cortisol awakening responses in patients with borderline personality disorder: gender and trait aggressiveness matter. Psychoneuroendocrinology. 2015; 55: 116–27.
  522. Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM–IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007; 62(6): 553–64.
  523. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 2003; 160(2): 274–83.
  524. Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007; 27(8): 959–85.
  525. Kane JM, Jeste DV, Barnes TR: Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington, D.C: American Psychiatric Association; 1992. Ref Type: Report.
  526. Ebert A, Kolb M, Heller J, Edel MA, Roser P, Brüne M. Modulation of interpersonal trust in borderline personality disorder by intranasal oxytocin and childhood trauma. Soc Neurosci. 2013; 8(4): 305–13.
  527. Bertsch K, Gamer M, Schmidt B, et al. Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. Am J Psychiatry. 2013; 170(10): 1169–77.
  528. Amad A, Thomas P, Perez-rodriguez MM. Borderline Personality Disorder and Oxytocin: Review of Clinical Trials and Future Directions. Curr Pharm Des. 2015; 21(23): 3311–6.
  529. Bateman A, Fonagy P. Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. Am J Psychiatry. 2001; 158(1): 36–42.
  530. Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry. 2009; 166(12): 1355–64.
  531. Закон Российской Федерации от 2 июля 1992 г. № 3185-I (ред. от 21.11.2011 г.) «О психиатрической помощи и гарантиях прав граждан при ее оказании», ст. 27.
Назад: Благодарности
Дальше: Список фильмов и книг для тех, кому интересна психиатрия

Юлий
Интересно прочитать о своих "перспективах"
Аня
Почитать
Виктория
Интересно...ненаучно о научном))